Curium approach puts Lantheus deal value near $7B
Lantheus is weighing a potential sale after an approach from Curium Pharma, while company filings show recent Pylarify pressure and pending PET regulatory milestones.
Lantheus Holdings has received a takeover approach from Curium Pharma that would value the radiopharmaceutical company at about $7B. The companies have discussed a potential transaction, but no final decision has been made.
Curium and CapVest announced a separate recapitalization in November 2025 through a new continuation vehicle. That transaction valued Curium at about $7B, according to the companies.
Lantheus reported $377.3M in worldwide revenue for Q1 2026, up 1.2% from the prior-year period. PYLARIFY sales were $240.9M, down 6.5%, while Neuraceq sales were $35.4M and DEFINITY sales were $84.6M.
The company also kept its 2026 guidance unchanged at $1.4B to $1.45B in revenue and $5.00 to $5.25 in adjusted diluted EPS. Lantheus said the year remains focused on PSMA PET, Alzheimer’s imaging, prioritized pipeline work, and radiodiagnostic capital deployment.
Regulatory timing remains part of the company’s 2026 calendar. In March, Lantheus said the FDA extended the PDUFA date for LNTH-2501, a PET diagnostic imaging kit for somatostatin receptor-positive neuroendocrine tumors, to June 29 to review manufacturing-related information.
FDA approval of PYLARIFY TruVu was another Q1 2026 milestone. Lantheus said the new formulation is planned for a phased geographic commercial launch beginning in Q4 2026, aligned with coding, coverage, payment, customer, and manufacturing readiness.
A securities class-action complaint filed in September 2025 also remains part of Lantheus’ recent backdrop. The complaint alleges that the company and certain executives misled investors about PYLARIFY’s competitive position, pricing dynamics, and 2025 revenue outlook.
Sources
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Pathology support broadens MedDream viewer scope
Version 8.9.0 is scheduled for June 2026 through aycan and will add support for pathology workflows and saving reconstructed MPR viewports as new study series.
DOSIsoft unit gives PLANET a theranostics focus
DOSIsoft Theranostics will operate within the DOSIsoft group, with its own partnerships and investment strategy centered on PLANET software.
Vault-ready proton system headed to Tam Anh
Mevion said the S250-FIT installation would be Vietnam’s first proton therapy system, with operation expected as early as late 2027 at Tam Anh’s Phu My Hung facility.
I-MED sale gives Jardines 215-clinic radiology network
Jardine Matheson will acquire 100% of I-MED Radiology Network in a deal valued at A$3.4B, including I-MED’s minority stake in Harrison.ai.
Expected Russell addition puts Hyperfine in small-cap benchmarks
FTSE Russell’s preliminary June reconstitution list includes Hyperfine, with index changes set to take effect after U.S. markets close on June 26.
Niowave Lansing site to scale Ac-225 supply by 2028
The Lansing, MI, site will house superconducting linear accelerators and radiochemistry systems to support scalable actinium-225 production, with completion expected in 2028.
30-year GE-UW tie expands into CT and theranostics research
The collaboration will focus on CT and molecular imaging technologies for cardiology, oncology, and theranostics workflows at UW Medicine Radiology facilities in Seattle.
Recall issues and isotope shortages weigh on Radnostix Q1 revenue
The radioisotope-focused company reported $2.38M in Q1 revenue, citing recall impacts, isotope shortages, and Cobalt-60 hot cell downtime.
Ephemeral to build AI data platform for Plus CNS oncology programs
The companies will develop an AI platform to integrate therapeutic, diagnostic, and bioinformatics data across Plus Therapeutics’ CNS oncology programs.
Fujifilm balloon-free EBUS scope targets pulmonary setup time
The EB-710US Ultrasound Bronchoscope is designed for pulmonary procedures and will be demonstrated at the American Thoracic Society Conference.
ACIST Pro brings contrast tracking upgrade to U.S. cath labs
The Bracco company received U.S. clearance and launched ACIST Pro, a variable-rate contrast management system for image-guided cardiovascular procedures.
Braid Health launches $199 radiology second-opinion service
Patients can upload MRI, CT, X-ray, or ultrasound files and receive a written second opinion from a board-certified U.S. radiologist.